OPKO Health, Inc. OPK
1.61 USD -0.08 (-4.73%)
Regular-session close
1.58 -0.03 -1.86%
Pre-market · Nov 20, 4:01 AM ET
1.59 Day range 1.71
0.98 52-week range 1.86
- YTD
- +27.78%
- 1 year
- +23.85%
News
zacks.com Here's Why You Should Retain OPK Stock in Your Portfolio for Now OPKO Health's Global Products growth, partnered therapies and advancing pipeline support its outlook, but clinical risks and market headwinds pose challenges.
benzinga.com Why Pony AI Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket Pony AI rose 10.6% after beating Q3 loss estimates but missing sales; Autozi led gainers, while IRIDEX fell 17.6% on results and guidance.benzinga.com CORRECTION: OPKO Health Q3 EPS $(0.05) Beats $(0.06) Estimate, Sales $65.400M Miss $141.267M Estimate OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 25 percent decrease over losses of $(0.04) per…
benzinga.com OPKO Health Q3 2026 Earnings Call Transcript OPKO Health (NASDAQ:OPK) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…benzinga.com OPKO Health Q3 EPS $(0.07) Misses $(0.06) Estimate, Sales $65.400M OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 30 percent increase over losses of $(0.10)…
benzinga.com OPKO Biologics Doses First Patient In Its Phase 1/2a Clinical Study Of OPK-8801001 To Treat Acromegaly OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of OPK-8801001, an investigational,…
benzinga.com Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.
